Dairy Probiotic Foods and Bacterial Vaginosis: A Review on Mechanism of Action by Bastani, Parvin et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 20 
 
 
 
 
© 2012 Ziyadi et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Dairy Probiotic Foods and Bacterial Vaginosis:  
A Review on Mechanism of Action 
Parvin Bastani, Aziz Homayouni,  
Violet Gasemnezhad Tabrizian and Somayeh Ziyadi 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/50083 
1. Introduction 
Bacterial vaginosis (BV) is the most common urogenital disease in women, affecting about 
19-24% of them in reproductive ages. 10-26% of pregnant women in the United States have 
been reported to suffer from BV. The prevalence of BV varies in different parts of the world 
and is higher in developing countries. The disease has been found in 12 to 25 percent of 
women in routine clinic populations, and accounts for 32 to 64 percent of women in clinics 
for sexually transmitted diseases; however, there is still some controversy about whether or 
not BV is a sexually transmitted disease (STD) in the “traditional” sense. Current data 
indicate that the overall prevalence of BV is much higher among STD clinic attendees and 
commercial sex workers [1]. BV is believed to occur as a result of an imbalance in the normal 
vaginal microbiota [2] when the normal Lactobacillus bacteria in the vagina are disrupted 
and subsequently replaced by predominantly anaerobic bacteria including Gardnerella 
vaginalis, Mycoplasma hominis, Prevotella, and Peptostreptococcus [3]. Other bacteria such 
as Escherichia coli from the rectum have also been shown to cause the disease. Lactobacilli 
bacteria, by producing a natural antibacterial, hydrogen peroxide, keep the healthy normal 
balance of vaginal microorganisms. Factors that upset this balance in the vagina are not 
well-understood. However, the activities or behaviours that have been related with BV 
incidence include having a new sex partner or multiple sex partners and douching [4, 5]. BV 
is mainly followed by irritating symptoms mainly foul, fish-like or musty odor which is 
sometimes stronger after a woman has sex, watery or foamy, white (milky) or gray vaginal 
secretions, itching on the outside of the vagina and Burning or discomfort during urination 
[6]. It is also known that BV is associated with potentially severe gynaecological and 
obstetric complications. Current data suggest a causal association between BV, pelvic 
inflammatory disease and tubal factor infertility [7]. Pregnant women with BV have a higher 
risk of adverse outcomes such as late miscarriage, chorioamnionitis, premature rupture of 
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membranes, preterm birth and postpartum endometritis; they are more susceptible to 
having babies of low birth weight as well [8, 9]. BV has been identified as a risk factor for 
herpes virus type 2 infections and increased viral shedding in infected women [10, 11]. It has 
also been suggested that the presence of BV increases the risk for human immunodeficiency 
virus infection [12]. It is noteworthy that many women with BV do not show any symptoms 
[13], pelvic inflammatory disease [14], infections following gynecological surgery [15] and 
pre-term birth. BV is not transmitted through toilet seats, bedding, swimming pools, or 
touching of objects. Women, who have not had sexual intercourse, hardly develop BV [16]. 
Typically, a cure for BV refers to resolution of symptoms and maybe a repeat BV-negative 
screen. We know from clinical studies that BV has both an unprompted resolution and 
repetition [13]. As many as 30 percent of women relapse within 1 month of treatment, with 
unprompted relapse occurring more commonly among women treated with topical compared 
with systemic antibiotics [17]. The most common oral treatment for BV in both pregnant and 
non-pregnant women is metronidazole and clindamycin [18]. The individual cure rate given a 
7-day, twice-daily course of 500 mg of metronidazole ranges from 84 percent to 96 percent, and 
the cure rate given a 2 g single dose of metronidazole is 54-62 percent [19]. The second systemic 
treatment for BV is oral clindamycin. The one known clinical trial conducted describing the 
efficacy of oral clindamycin reported that a 300-mg, twice-daily course of clindamycin for 7 
days resulted in a 94 percent cure rate [15]. The two topical treatments for BV include 
metronidazole 0.75 percent vaginal gel and clindamycin 2 percent vaginal cream [5].  
Probiotics have been documented to be beneficial in curing BV as well as reducing its 
recurrence and have been administered both orally and vaginally [20]. Oral administration 
introduces the beneficial bacteria directly into the vagina; probiotics consumed orally are 
believed to ascend to the vaginal tract after they are excreted from the rectum. Mechanism 
through which probiotics play a role in BV treatment include: [1] occupation of specific 
adhesion sites at the epithelial surface of the urinary tract; [2] maintenance of a low pH and 
production of antimicrobial substances like acids, hydrogen peroxide and bacteriocins; [3] 
degradation of polyamines; and [4] the production of surfactants with antiadhesive 
properties [21]. Probiotics have been shown to exert the beneficial effects both in foods such 
as yoghurt [22], ice cream [23, 24], and supplements [25]. However, foods may be preferred 
by patients since BV is not considered a disease by public and the affected women may not 
want to be prescribed supplements.  
The purpose of the present chapter is to review recent research into aspects influencing the 
impact probiotics have on bacterial vaginosis. All papers published between 1990 and 2011 
were searched in Pubmed and Science Direct, using probiotic, bacterial vaginosis and 
urinary tract infections (UTI) as key words; only clinical trials were included. 
2. Probiotics  
2.1. History 
The expression “probiotic” was probably first defined by Kollath in 1953, when he 
suggested the term to denote all organic and inorganic food complexes as “probiotics” in 
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contrast to harmful antibiotics, for the purpose of upgrading such food complexes as 
supplements [26]. In 1998, probiotics were described as “live microorganisms which, when 
ingested in adequate amounts, confer a health benefit”. The term “probiotic” is an 
etymological hybrid derived from Greek and Latin meaning “for life” [27]. The original 
observation of the positive role played by some selected bacteria is attributed to Eli 
Metchnikoff, who extolled the virtues of consuming fermented dairy products and 
postulated his "Longevity without aging" theory, in which he claimed that lactic bacteria by 
replacing the harmful bacteria indigenous to the intestines, prolong life. The Russian born 
Nobel Prize recipient, working at the Pasteur Institute at the beginning of the last century 
suggested that the dependence of the intestinal microbes on the food makes it possible to 
adopt measures to modify the flora in our bodies and to replace the harmful microbes by 
useful microbes [28].  
2.2. Definition 
Presently, there is general agreement that a ‘‘probiotic’’ refers to viable microorganisms that 
promote or support a beneficial balance of the autochthonous microbial population of the 
gastrointestinal tract [29, 30]. Probiotics are defined as live microorganisms which, when 
consumed in appropriate amounts, confer a health benefit on the host, by FAO/WHO [31]. 
When ingested, some of these probiotic microorganisms are able to resist the 
physicochemical conditions prevailing in the digestive tract [32]. The strains most frequently 
used as probiotics belong to the genera bifidobacterium and Lactobacillus [33]. Some of the 
species used in probiotic products are: 1) Lactic acid producing bacteria (LAB): 
Lactobacillus, bifidobacterium, streptococcus; 2) Non-lactic acid producing bacterial species: 
Bacillus, propionibacterium; 3) Nonpathogenic yeasts: Saccharomyces; 4) Non-spore 
forming and non-flagellated rod or coccobacilli [31]. 
2.3. Health benefits 
Some mostly documented health effects of probiotics are: relieving diarrhea, improving 
lactose intolerance, relief of respiratory and urinary tract infections and its 
immunomodulatory, anticarcinogenic, antidiabetic, hypocholesterolemic and hypotensive 
properties [25, 34, 35]. LAB also have some other advantageous effects such as vitamin 
synthesis, improvement of mineral and nutrient absorption, deprivation of antinutritional 
factors, and/or modulation of GI physiology and reduction of pain perception. Special 
probiotic strains may induce the expression of receptors on epithelial cells that locally 
control the transmission of nociceptive information to the GI nervous system [36]. By 
reducing inflammatory responses, probiotics have been shown to correct insulin sensitivity 
and reduce development of diabetes mellitus [34]. A beneficial effect of ‘‘lactic acid 
producing’’ microorganisms on vaginal microflora has also been suggested more than 100 
years ago [37]. There are differing degrees of evidence supporting the verification of such 
effects, and the consultation recognizes that there are reports showing no clinical effects of 
certain probiotic strains in specific situations [38].  
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3. Probiotic and bacterial vaginosis 
Since antimicrobial treatment of urogenital infections is not constantly effectual and 
problems remain due to bacterial and yeast resistance, recurrent infections as well as side 
effects, it is no wonder why alternative remedies are sought for, by patients and their 
caregivers [39, 40]. The basis for use of probiotics in BV treatment emerged in 1973, when 
healthy women with no history of UTI were reported to have lactobacilli in their vagina [39]. 
Lactobacillus organisms that predominate in the vagina of healthy women spread from their 
rectum and perineum and form a barrier to the entry of uropathogens from vagina into the 
bladder [41]. 
Probiotics are believed to protect the host against infections by means of several 
mechanisms including: [1] occupation of specific adhesion sites at the epithelial surface of 
the urinary tract; [2] maintenance of a low pH and production of antimicrobial substances 
like acids, hydrogen peroxide, and bacteriocins; [3] degradation of polyamines; and [4] the 
production of surfactants with antiadhesive properties [21, 42]. 
There are important issues to which a great attention must be paid regarding the effects of 
probiotics on BV treatment and prevention. Probiotics have been administered both orally 
and vaginally; however it is still not clear as to which route is more efficient. Foods and 
supplements have been used as carriers when oral administration was aimed; no studies 
have compared the efficacy of these two vehicles. Not all strains have exerted the desired 
effects in the patients; poor colonization of some strains in the vagina could be a reason [39, 
40, 43]. The most profitable dose and treatment duration must be taken into consideration as 
well.  
3.1. Route of administration 
Probiotics must colonize the vagina to confer the benefits claimed for them; therefore they 
have to reach the organ intact. Vaginal probiotic capsules have widely been used, by the 
means of which, the probiotic bacteria are directly introduced into the vagina; however, in 
an attempt to come up with a more practical route which could also prevent BV in healthy 
women as well as presenting the consumer with other health benefits of these beneficial 
microorganisms, probiotics were administered orally [41, 43]. Researchers assumed that, 
similar to pathogenic bacteria with colonic origin which cause urogenital disorders, 
probiotic bacteria must be capable of ascending to the vaginal tract after being excreted from 
the rectum (Figure 1). This application is also justified by observations that the normal 
vaginal microflora colonizes from an intestinal origin which means that microbial ascension 
is a natural process actually contributing to a the development of a healthy vaginal 
microflora in the host [39]; this has been shown by a number of clinical trials as well [41, 44]. 
Thus far, no clinical trials have compared the efficacy of probiotics when administered 
vaginally versus orally. In tables 1-2, clinical trials performed in this regard have been 
summarized. It appears that vaginal administration has no predominance to oral 
consumption of probiotics, when it comes to treating BV. 
 
Dairy Probiotic Foods and Bacterial Vaginosis: A Review on Mechanism of Action 449 
(1) occupation of specific adhesion 
sites at the epithelial surface 
(2) Decreasing pH and production 
of antimicrobial substances
(3) degradation of polyamines
(4) production of surfactants with 
antiadhesive properties
 
Figure 1. Capability of pathogenic and probiotic bacteria to ascend the vagina after being excreted from 
rectum 
Type Strain Dose Period Heath condition Effect Ref. 
Yoghurt Lactobacillus 
acidophilus 
 
1.0 × 108
CFU 
Once daily for 
2 month 
Bacterial 
vaginosis, 
candidiasis
Reduction in BV episodes at 1 mo was 
60% for probiotic yoghurt vs 25% for 
pasteurized
[45] 
Capsules 
 
Lactobacillus 
rhamnosus GR-1 plus 
Lactobacillus 
fermentum RC-14 or L. 
rhamnosus
108 CFU Each day for 
28 days 
 
Bacterial 
vaginosis 
 
Normal vaginal flora was restored using 
specific probiotic strains administered 
orally 
[41] 
Skim 
milk 
Lactobacillus 
rhamnosus GR-1 and 
Lactobacillus 
fermentum RC-14
109 CFU Given twice 
daily for 14 
days 
Bacterial 
vaginosis 
Treatment correlated with a healthy 
vaginal flora in up to 90% of patients 
[46] 
 
Capsule 1- L. rhamnosus GR-1 ⁄ 
L. fermentum RC-14 
2-L. rhamnosus 
GR-1 ⁄ L. fermentum 
RC-14 
3-L. rhamnosus 
GR-1 ⁄ L. fermentum 
RC-14
8 × 108
CFU 
1.6 ×109 
CFU 
 
6 × 109 
CFU 
Day orally
for 28 days 
 
History of
BV 
Through 6 weeks after treatment with 
probiotics, Nugent score decreased, 
indicative of BV resolution 
[43]  
Capsule 
 
L. rhamnosus
GR-1 + L. fermentum 
RC-14
>109 CFU
 
Once-daily for
60 days 
Bacterial 
vaginosis 
Probiotics colonized the vagina 
properly and the Nugent score 
normalized after the treatment 
[47]  
Capsules 
 
Lactobacillus rhamnosus 
GR-1 and Lactobacillus 
fermentum RC-14
109 CFU
 
60 days
 
Urogenital 
infections 
Lactobacilli counts increased while 
yeast and coliforms decreased 
significantly after supplementation 
[48]  
 
Capsule 
 
Lactobacillus reuteri 
RC-14 Lactobacillus 
rhamnosus GR-1 
 
109 CFU
 
Twice daily 
from days 1 to 
30 
 
Bacterial 
vaginosis 
 
88% were cured in the 
antibiotic/probiotic group compared to 
40% in the antibiotic/placebo group [p < 
0.001]. High counts of Lactobacillus sp. 
Colonized the vagina properly
[49] 
 
 
Capsules 
 
Lactobacillus
rhamnosus GR-1 and 
Lactobacillus reuteri 
RC-14 
1.0 × 109
CFU 
 
BID
for 30, after 
500 mg 
metronidazole 
BID PO for 7 d
Bacterial 
vaginosis 
 
BV cure rate was 88% in probiotic group 
vs. 40% in placebo group 
 
[42] 
 
 
Capsules 
 
Lactobacillus 
rhamnosus GR-1 and 
Lactobacillus 
reuteri RC-14
2.5 × 109
CFU 
 
14 days
 
Bacterial 
vaginosis 
 
The median difference in
Nugent scores between baseline and the 
end of the study was 3 in the intervention 
group and 0 in the control group
[50] 
 
Table 1. The effects of oral administration of probiotics on BV, performed between 1990 and 2011 
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Type Strain Dose Period Heath 
condition
Effect Ref. 
10–15 mL 
yoghurt, vaginal 
douche 
 
L acidophilus 1.0×108
CFU 
BID for 7 d
 
 
First trimester 
of pregnancy 
with BV 
diagnosis
BV cure rate was 88% probiotic 
group at 4 and 8 w and 38% in 
control group 
[51] 
 
 
Vaginal tablets 
 
L acidophilus and 
oestriol 0.03 mg 
 
106 CFU
 
Once daily or 
twice daily for 
6 days 
Bacterial 
vaginosis 
 
Microbiological cure [Nugent 
criteria] and clinical cure were 
observed on days 15 and 
28 post intervention
[1] 
 
Tampons 
 
L.gasseri, L casei 
var rhamnosus & L 
fermentum
108 CFU
 
5 tampons 
during 
menstruation
Bacterial 
vaginosis 
Microbiological cure was 
observed based on Nugent score 
and Amsel criteria
[2] 
Vaginal tablet 
 
Lactobacillus
acidophilus, 0.03 
mg oestriol and 600 
mg lactose.
> 107 CFU Daily for 6 days
 
Vaginal 
infections 
 
Vaginal flora was enhanced 
significantly by the probiotic 
administration in combination 
with low dose oestriol
[52] 
 
Capsules L rhamnosus GR1, 
L reuteri RC14 
 
1× 109
CFU 
 
Bedtime for 5 
consecutive 
days 
Bacterial 
vaginosis 
 
Microbiological cure at days 6, 15 
and 30 and clinical cure at days 6, 
15, and 30 were reported 
[42] 
 
Vaginal tablet 
 
Lactobacillus
rhamnosus 
> 4×104
CFU 
Once a week at 
bedtime for 
two months 
Bacterial 
vaginosis 
Significant difference between 
the two treatment groups were 
seen at day 90
[53] 
 
Vaginal tablets 
 
L. brevis
L. salivarius subsp
salicinius , and 
L.plantarum
109 CFU
 
7 days
 
Bacterial 
vaginosis 
 
All of the patients in the probiotic 
group were free of BV, showing a 
normal or intermediate vaginal 
flora
[4] 
 
Vaginal 
application 
 
40 mg of 
Lactobacillus 
rhamnosus 
> 4×104 
CFU 
for 6 months
 
Prevent the 
recurrence of 
bacterial 
vaginosis
The vaginal administration of the 
probiotic allows stabilization of 
the vaginal flora and reduces BV 
recurrence
[54] 
 
Vaginal 
Capsules 
L gasseri LN40, 
Lactobacillus 
fermentum LN99, L. 
casei subsp. 
rhamnosus LN113 
and 
P. acidilactici LN23
Between 
108 and 
1010 CFU
 
Five days, after 
conventional 
treatment of 
bacterial 
vaginosis 
 
Bacterial 
vaginosis, 
vulvovaginal 
candidiasis 
LN had a good colonization rate 
in the vagina BV patients and 
women receiving LN were cured 
2-3 days after 
Administration 
[55] 
 
 
 
Vaginal capsule 
 
Lactobacillus 
rhamnosus, L 
acidophilus, and 
Streptococcus 
thermophiles
108 CFU
 
21 days, for 7 
days on 7 days 
off, and 7 days 
on. 
Prophylaxis 
bacterial 
vaginosis 
 
Probiotic prophylaxis resulted in 
lower recurrence rates for 
BV women 
[3] 
 
Table 2. The effects of vaginal administration of probiotics on BV, performed between 1990 and 2011 
3.2. Administration vehicles 
As for administration route, no studies by now have investigated the efficacy of foods 
versus supplements in exerting the benefits expected from the probiotics. Supplements 
have been used in a greater number of studies in BV patients and the number of studies in 
which foods were opted as probiotic vehicles are limited. Consumption of fermented milk 
containing lactobacilli has been found to reduce BV episodes [45]. Supplements have been 
used in a variety of forms including oral capsules, vaginal tablets and vaginal capsules. 
Clinical trials in which patients were administered oral capsules, reported a positive effect 
of the treatment on BV [39, 41-43, 49, 56]. Vaginal probiotic tablets were reported to be 
effective in alleviating BV symptoms and decreasing its recurrence [1, 4, 52, 53]. Vaginal 
capsules have also been reported to efficiently ease BV symptoms in some studies [3, 42, 
50, 55].  
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3.3. Appropriate strains for treatment of bacterial vaginosis 
Various in-vitro studies have shown that specific strains of lactobacilli inhibit the growth of 
bacteria causing BV by producing H2O2, lactic acid, and/or bacteriocins and/or inhibit the 
adherence of G. vaginalis to the vaginal epithelium [52]. According to a general theory a 
probiotic must have two criteria to be selected as an efficient strain in the treatment of 
urogenital infections: 1] It must be able to colonize the host without any adverse side effects 
and 2] It must be capable of inhibiting urogenital pathogens [57]. According to Reid and 
colleagues [43] different probiotic bacteria have varying capabilities to colonize the vagina 
of different patients; this indicates the importance of using a combination of strains in 
probiotic products. Oral administration of L. acidophilus, or intra-vaginal administration of 
L. acidophilus or L. rhamnosus GR-1 and L. fermentum RC-14, have been documented to 
most efficiently increase the numbers of vaginal lactobacilli, restore the vaginal microbiota 
to normal, and cure women of BV [52]. 
3.4. Appropriate dose for treatment of bacterial vaginosis 
Researchers have tried different dosages in their attempts to treat BV with probiotics, many 
of which have resulted in positive outcomes. There is strong evidence that BV is most 
appropriately treated when over 10^8 viable organisms per day is used [41]. However, the 
minimum dose which can generally confer the favored benefits in women must to be 
determined. 
3.5. Effect of treatment duration 
What BV patients and their caregivers are mostly looking for, is a treatment protocol to get 
them rid of the recurrence of the infection. Probiotics are a good option to fulfill this goal, 
provided that they are properly colonized in the vagina. Parent and colleagues [1] found 
that cure was more common, and the number of vaginal lactobacilli was significantly 
higher, in women with BV at both 2 and 4 weeks after the start of a 6-day treatment with L. 
acidophilus and oestriol, when compared to women with BV who received a placebo. 
However, most clinical trials have reported that 2 months of oral administration of L. 
acidophilus, Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 can be more effective 
in preventing recurrences of BV and/or increasing vaginal colonization with lactobacilli, 
thus restoring the normal vaginal microbiota [58]. 
4. Conclusion 
This study confirms the potential efficacy of lactobacilli as a non-chemotherapeutic means to 
restore and maintain a normal urogenital flora, and shows that probiotic bacteria especially 
L. acidophilus, L. rhamnosus GR-1 and L. fermentum RC-14 when administered over 10^8 
CFU for 2 months can most appropriately normalize vaginal flora, help cure the existing 
infection and prevent recurrence of BV. Longer periods of probiotic administration may be 
useful for long term control of BV relapses after conventional therapy with metronidazole. 
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Probiotics have been reported useful when used either vaginally or orally; foods and 
supplements have both been shown to be efficient vehicles as well; however, since BV is a 
common disorder for the prevention of which, the vaginal flora needs to be normal and 
devoid of pathogens by the help of beneficial bacteria, suggesting women to consume 
probiotic foods will not only protect them against BV, but will also reward them with other 
health benefits of probiotics. 
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